Market Place
Sourcing Support
Bone Therapeutics` final asset buried after phase 2 fail
20 Jun 2023 //
FIERCE BIOTECH
Bone Therapeutics breaks off old name, rebrands as BioSenic
26 Oct 2022 //
FIERCEPHARMA
Bone to start a new Euronext equity story with a change of name to BioSenic
25 Oct 2022 //
GLOBENEWSWIRE
Bone Therapeutics provides Third Quarter 2022 Business Update
21 Oct 2022 //
GLOBENEWSWIRE
Bone Therapeutics SA: Transparency notification received from S.F.P.I/F.P.I.M
10 Oct 2022 //
GLOBENEWSWIRE
Bone Therapeutics to regain worldwide rights to ALLOB
07 Oct 2022 //
GLOBENEWSWIRE
Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022
06 Oct 2022 //
GLOBENEWSWIRE
Bone Therapeutics Information on the total number of voting rights and shares
30 Aug 2022 //
GLOBENEWSWIRE
Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022
26 Aug 2022 //
GLOBENEWSWIRE
A complex fracturing at Bone brings orthopedic biotechs in reverse merger deal
10 Aug 2022 //
FIERCE BIOTECH
Bone Tx broadens portfolio by acquiring majority participation in Medsenic
09 Aug 2022 //
GLOBENEWSWIRE
Bone Therapeutics: Information on the total number of voting rights and shares
29 Jul 2022 //
GLOBENEWSWIRE
Bone breaks from original cell therapy plan, switching endpoint
15 Jul 2022 //
FIERCEBIOTECH
Bone Therapeutics optimizes and introduces analysis in ongoing ALLOB PIIb study
14 Jul 2022 //
GLOBENEWSWIRE
Bone Therapeutics: Information on the total number of voting rights and shares
29 Jun 2022 //
GLOBENEWSWIRE
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
13 Jun 2022 //
GLOBENEWSWIRE
Bone Therapeutics Provides First Quarter 2022 Business Update
01 Jun 2022 //
GLOBENEWSWIRE
Bone Therapeutics signs definitive subscription agreement of EUR 5M with ABO
31 May 2022 //
GLOBENEWSWIRE
Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
12 May 2022 //
GLOBENEWSWIRE
Bone Therapeutics to host Annual General Meeting
09 May 2022 //
GLOBENEWSWIRE
Bone Therapeutics announces 2021 full year results
29 Apr 2022 //
GLOBENEWSWIRE
Bone Therapeutics Secures EUR 5 Million Financing
12 Apr 2022 //
GLOBENEWSWIRE
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
29 Mar 2022 //
GLOBENEWSWIRE
Bone Therapeutics: Transparency notification received from Nyenburgh Holding NV
23 Mar 2022 //
GLOBENEWSWIRE
Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
18 Jan 2022 //
GLOBENEWSWIRE
Bone Therapeutics SA: Transparency notification received from Nyenburgh
09 Dec 2021 //
GLOBENEWSWIRE
Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement
02 Dec 2021 //
GLOBENEWSWIRE
Link Health to obtain global rights for Bone Therapeutics’ cell therapy
29 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Bone, Link Health sign a non-binding term sheet for global rights of ALLOB
29 Nov 2021 //
GLOBENEWSWIRE
Bone Therapeutics appoints Scientific Advisory Board for iMSC cell& gene therapy
11 Oct 2021 //
GLOBENEWSWIRE
Bone signs research partnership with Implant Therapeutics to (iPSC)
27 Sep 2021 //
GLOBENEWSWIRE
Bone Therapeutics reports half year 2021 results
08 Sep 2021 //
GLOBENEWSWIRE
Bone Therapeutics Phase 3 Viscosupplement JTA-004 study Failed to Meet Endpoints
03 Sep 2021 //
TRIALSITENEWS
Bone Therapeutics Phase 3 Viscosupplement JTA-004 study Failed to Meet Endpoints
03 Sep 2021 //
TRIALSITENEWS
Bone Therapeutics announces PIII results for osteoarthritis study in JTA-004
30 Aug 2021 //
GLOBENEWSWIRE
Bone Therapeutics implements financing agreement with EIB & receives first €8.0M
27 Aug 2021 //
GLOBENEWSWIRE
Bone Therapeutics SA: Notice of Extraordinary Shareholders’ Meeting
05 Aug 2021 //
GLOBENEWSWIRE
Bone Therapeutics appoints Anne Leselbaum, MD as Chief Medical Officer
12 Jul 2021 //
GLOBENEWSWIRE
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
12 Jan 2021 //
GLOBENEWSWIRE
Bone Therapeutics completes recruitment and patient treatment in JTA-004
22 Dec 2020 //
GLOBENEWSWIRE
Bone completes recruitment and patient treatment in JTA-004
22 Dec 2020 //
GLOBENEWSWIRE
Catalent completes acquisition of Bone Therapeutics’ cell therapy manufacturing
16 Nov 2020 //
PHARMABIZ
Bone Therapeutics Provides Third Quarter 2020 Business Update
30 Oct 2020 //
GLOBENEWSWIRE
Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility
30 Oct 2020 //
CONTRACTPHARMA
Bone , Link Health and Pregene to develop and commercialize the ALLOB allogeneic
03 Oct 2020 //
GLOBENEWSWIRE
Bone Therapeutics announces expansion of its pipeline supported by funding
20 Aug 2020 //
PHARMIWEB
Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004
13 Aug 2020 //
GLOBENEWSWIRE
Bone Therapeutics gets Denmark approval to begin JTA-004 phase III
23 Mar 2020 //
PHARMABIZ
